---
document_datetime: 2025-10-28 12:31:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/kisunla-epar-all-authorised-presentations_en.pdf
document_name: kisunla-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7630899
conversion_datetime: 2025-12-22 08:06:33.81293
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-----------------------------|
| EU/1/25/1926/001 | Kisunla           | 350 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 20 ml (17.5 mg/ml)        | 1 vial                      |
| EU/1/25/1926/002 | Kisunla           | 350 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 20 ml (17.5 mg/ml)        | 2 (2 x 1) vials (multipack) |